Stanford BMT-CT ASTCT Abstracts 2024: Oral

9 Assessment of Central Nervous System Responses in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Receiving Brexucabtagene Autoleucel As an FDA-Approved Standard of Care

Wednesday, February 21, 2024

 3:45 PM - 4:00 PM CST

Stars at Night B2 & B3 (Ballroom Level, HBGCC)

Ibrahim N. Muhsen, MD, Section of Hematology Oncology, Department of Medicine, Baylor College of Medicine, Houston, TX, Gregory Roloff, MD, Hematology/Oncology, University of Chicago, Chicago, IL, Noam E. Kopmar, MD, Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA, Santiago Mercadal, MD, University of Utah, Salt Lake City, UT, Timothy E O'Connor, MD, Loyola University Medical Center, Maywood, IL, Kaitlyn C Dykes, MD, University of California San Diego, La Jolla, CA, Mohamed Ahmed, MD, Cedars-Sinai Medical Center, Los Angeles, CA, Simone E. Dekker, MD, PhD, Department of Medicine, Oregon Health & Science University, Portland, OR, Nikeshan Jeyakumar, MD, Stanford University School of Medicine, Stanford, CA, Muthu Veeraputhiran, MD, MPH, Hematology Oncology, University of Arkansas for Medical Sciences, Little Rock, AR, Akash Mukherjee, MD, Hematology, Stem cell transplantation and Cellular therapy, University of Arkansas for Medical Sciences, Little Rock, AR, Aaron C. Logan, MD PhD, Div. Hematology, BMT, & Cellular Therapy, University of California, San Francisco, San Francisco, CA, Dr. Stephanie B. Tsai, MD, Hematology/Oncology, Loyola University Medical Center, Maywood, IL, Jessica T. Leonard, MD, Center for Hematologic Malignancies - Knight Cancer Institute, Oregon Health & Science University, Portland, OR, Marc Schwartz, MD, University of Colorado, Aurora, CO, Joshua P Sasine, MD, Medicine, Division of Hematology and Oncology, University of California, Los Angeles, Los Angeles, CA, Ryan D. Cassaday, MD, Fred Hutchinson Cancer Center, Seattle, WA, Bijal D. Shah, MD, H. Lee Moffitt Cancer Center, Tampa, FL, Lori S Muffly, MD, MS, Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University, Stanford, CA, LaQuisa Chimere Hill, MD, Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX and Ibrahim Aldoss, MD, Hematology and HCT, City of Hope, Duarte, CA

https://tandem.confex.com/tandem/2024/meetingapp.cgi/Paper/23827

25 Donor Search and Selection Strategy to Facilitate Comparable Transplant Rates across Donor Search Prognosis Groups: A Report from the BMT CTN 1702 Trial

Thursday, February 22, 2024

 3:45 PM - 4:00 PM CST

Stars at Night B2 & B3 (Ballroom Level, HBGCC)

Joseph A. Pidala, MD, PhD1, Brent Logan, PhD2, Naya He, MPH3, Stephanie J Lee, MD, MPH4, Stefan O. Ciurea, MD5, Steven M. Devine, MD6, Bronwen E. Shaw, MD, PhD7, Jenny Vogel, CCRP8, Connor Erickson, CCRP9, Asad Bashey, MD, PhD10, Jerry Doyle9, Nancy DiFronzo, PhD11, Nosha Farhadfar, MD12, Mike R. Grunwald, MD13, Brandon Hayes-Lattin, MD14, Lori Henderson, PhD15, William J. Hogan, MB BCh16, Mary M. Horowitz, MD, MS17, Eric Leifer18, Heather Symons, MD, MHS19, Dr. Iskra Pusic, MD, MSCI20, Samer A. Srour, MB ChB, MS21, Sally Arai, MD22, Mark Juckett, MD23, Dianna S. Howard, MD24, Joseph Uberti, MD25, LaQuisa Chimere Hill, MD26, Sumithira Vasu, MBBS27 and Jason Dehn, MPH28, (1)Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, (2)CIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, (3)CIBMTR® (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, Medical College of Wisconsin, Milwaukee, WI, (4)Fred Hutchinson Cancer Center, Seattle, WA, (5)Division of Hematology/Oncology, Department of Medicine, Hematopoietic Stem Cell Transplantation and Cellular Therapy Program, University of California, Irvine, Orange, CA, (6)CIBMTR® (Center for International Blood and Marrow Transplant Research), National Marrow Donor Program/Be The Match, Minneapolis, MN, (7)CIBMTR® (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, (8)CIBMTR, National Marrow Donor Program, Minneapolis, MN, (9)NMDP, Minneapolis, MN, (10)The Blood and Marrow Transplant Program at Northside Hospital, Atlanta, GA, (11)Division of Blood Diseases and Resources, NIH/NHLBI Government Agency Partners, Bethesda, MD, (12)Department of Medicine, Division of Hematology & Oncology, University of Florida, Gainesville, FL, (13)Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, NC, Levine Cancer Institute, Charlotte, NC, (14)Center for Hematologic Malignancies - Knight Cancer Institute, Oregon Health & Science University, Portland, OR, (15)Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, MD, (16)Division of Hematology & Transplant Center, Mayo Clinic, Rochester, MN, (17)Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI, (18)NIH - NHLBI Government agency partners, Bethesda, MD, (19)Pediatric Oncology, Johns Hopkins Hospital, Baltimore, MD, (20)Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, MO, (21)MD Anderson Cancer Center, Houston, TX, (22)Division of BMT and Cellular Therapy, Stanford University School of Medicine, Stanford, CA, (23)Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, MN, (24)Stem Cell Transplant and Cellular Therapy Program, Wake Forest Baptist Comprehensive Cancer Center, Winston Salem, NC, (25)Division of Oncology, Karmanos Cancer Center/ Wayne State University, Detroit, MI, (26)Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX, (27)Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, (28)Vendor and Biorepository Services, National Marrow Donor Program/Be The Match, Minneapolis, MN

https://tandem.confex.com/tandem/2024/meetingapp.cgi/Paper/23711

31 Effective Prevention of Steroid-Requiring Chronic Gvhd with B Cell Depletion: A Randomized, Placebo-Controlled Trial

Thursday, February 22, 2024

 3:15 PM - 3:30 PM CST

Stars at Night B1 (Ballroom Level, HBGCC)

Corey Cutler, MD MPH1, Haesook T Kim, PhD2, Hassan El Banna2, Elizabeth Halloran3, Emily Matozel2, Vincent Ho4, John Koreth, MBBS, DPhil5, Mahasweta Gooptu, MD6, Roman M. Shapiro, MD2, Amar H. Kelkar, MD, MPH, FACP7, Chris J. Gibson, MD8, Carol Reynolds, PhD9, Michela Ansuinelli, MD2, Rayuko Tamada2, Chloe Au2, Zachariah DeFilipp, MD10, Areej El-Jawahri, M.D.11, Dr. Yi-Bin Chen, MD10, Najla El Jurdi, MD12, Daniel J. Weisdorf, MD12, Daniel R. Couriel, MD, MS13, Catherine J. Lee, MD, MS14, Bita Sahaf, PhD15, Juliana Craig, BA16, Kathleen Ji17, Robert Soiffer2, Joseph H. Antin, MD18, David B. Miklos, MD, PhD19 and Jerome Ritz, MD5, (1)Division of Transplantation and Cellular Therapy, Dana-Farber Cancer Institute, Boston, MA, (2)Dana-Farber Cancer Institute, Boston, MA, (3)Dana-Farber Cancer Institute, Boston, ME, (4)Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, (5)Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, (6)Division of Stem Cell Transplantation and Cellular Therapy, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, (7)Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, (8)Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, (9)Department of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, (10)Hematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital, Boston, MA, (11)Medicine, Division of Hematology & Oncology, Massachusetts General Hospital, Boston, MA, (12)Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, MN, (13)Blood and Marrow Transplant Program, Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, (14)Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, (15)Stanford University School of Medicine, Cancer Correlative Science Unit, Stanford Cancer Institute, Stanford, CA, (16)Department of Medicine, Division of Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, CA, (17)Stanford University Medical Center, Palo Alto, CA, (18)Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, (19)Division of BMT and Cellular Therapy, Stanford University School of Medicine, Stanford, CA

https://tandem.confex.com/tandem/2024/meetingapp.cgi/Paper/23463

39 Immune Engager Therapies Are Associated with Better Outcomes in Post Ide-Cel Relapse in MM- an Analysis of the US MM Immunotherapy Consortium Database.

Thursday, February 22, 2024

 3:45 PM - 4:00 PM CST

Stars at Night B4 (Ballroom Level, HBGCC)

Murali Janakiram, MBBS MS1, Jack Khouri2, Omar Castaneda, MD3, Leyla Shune4, Danai Dima5, Gurbakhash Kaur, MD6, Gabe De Avila7, Mahmoud Gaballa, MD8, Shonali Midha, MD9, James Davis, PharmD, BCOP5, Charlotte Wagner10, Joseph P McGuirk, DO11, Peter Forsberg12, Ran Reshef, MD13, Yi Lin, MD, PhD14,15, Aimaz Afrough, MD16, Larry D. Anderson Jr., MD, PhD16, Dr. Marco L. Davila, MD, PhD17, Mehmet H. Kocoglu, MD18, Douglas Sborov, MD19, Myo Htut, MD20, Hamza Hashmi, M.D.21,22, Surbhi Sidana, MD23, Arnab Chowdhury24, Krina K. Patel, MD, MSc25, Doris K Hansen, MD3 and Shebli Atrash26, (1)Division of Myeloma, City of Hope, Duarte, CA, (2)Blood and Marrow Transplant Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, (3)Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, (4)Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS, (5)US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, KS, (6)Hematologic Malignancies and Cellular Therapy, Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, (7)H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, (8)Bone Marrow Transplant and Cellular Therapy, Cancer Center, Massachusetts General Hospital, Boston, MA, (9)Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, (10)The University of Utah Huntsman Cancer Institute,, Salt Lake City, UT, (11)Division of Hematologic Malignancies and Cellular Therapeutics, The University of Kansas Cancer Center, Kansas City, KS, (12)UCHealth Blood Disorders and Cell Therapies Center - Anschutz Medical Campus, Aurora, CO, (13)Columbia University Herbert Irving Comprehensive Cancer Center, New York, NY, (14)Mayo Clinic, Rochester, MN, (15)Division of Hematology, Mayo Clinic, Rochester, MN, (16)Myeloma, Waldenstrom's and Amyloidosis Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, (17)Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, (18)Transplantation & Cellular Therapy Program, Division of Hematology/Oncology, Department of Internal Medicine, Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, (19)University of Utah/Huntsman Cancer Institute, Salt Lake CIty, UT, (20)City of Hope Comprehensive Cancer Center, Duarte, CA, (21)Hematology Oncology, Memorial Sloan Kettering Cance Center, New York, NY, (22)Memorial Sloan Kettering Cancer Center, Charleston, SC, (23)Division of BMT and Cellular Therapy, Stanford University School of Medicine, Stanford, CA, (24)city of hope, duarte, CA, (25)The University of Texas MD Anderson Cancer Center, Houston, TX, (26)Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, NC

https://tandem.confex.com/tandem/2024/meetingapp.cgi/Paper/23757

36 Safety and Efficacy of Axatilimab in Patients with Chronic Graft-Versus-Host Disease (AGAVE-201)

Thursday, February 22, 2024

 4:30 PM - 4:45 PM CST

Stars at Night B1 (Ballroom Level, HBGCC)

Zachariah DeFilipp, MD1, Stephanie J. Lee, MD, MPH2, Dr. Iskra Pusic, MD, MSCI3, Sally Arai, MD4, José Antonio Pérez-Simón, MD5, Arpita P Gandhi, MD6, Hannah Choe, MD7, Wendy Ingram8, Sandrine Loron9, Mohammad I Abu Zaid, MD10,11, Jennifer White12, Gizelle Popradi13, Amandeep Salhotra, MD14, Fabio Ciceri, MD, PhD15, Vedran Radojcic16, Timothy O’Toole16, Chuan Tian17, Peter Ordentlich, PhD18, Mehdi Hamadani19, Corey Cutler20, Daniel Wolff, MD21 and Carrie L. Kitko, MD22, (1)Hematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital, Boston, MA, (2)Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, (3)Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, MO, (4)Stanford Health Care, Stanford, CA, (5)Department of Hematology, Hospital Universitario Virgen del Rocio, Instituto de Biomedicina de Sevilla (IBIS) CSIC, Universidad de Sevilla, Spain, Sevilla, Spain, (6)Center for Hematologic Malignancies - Knight Cancer Institute, Oregon Health & Science University, Portland, OR, (7)7The James Cancer Hospital Solove Research Institute and The Ohio State University Wexner Medical Center, Columbus, OH, (8)University Hospital of Wales, Cardiff, United Kingdom, (9)HCL Centre Hospitalier Lyon Sud, Saint-Genis-Laval, France, (10)New York University Langone Health, New York, NY, (11)Department of Medicine, Division of Hematology and Oncology; Bone Marrow and Blood Stem Cell Transplantation Program, Indiana University, Indianapolis, IN, (12)The University of British Columbia, Vancouver General Hospital, Vancouver, BC, Canada, (13)McGill University Health Center - Research Institute, Montreal, QC, Canada, (14)City of Hope, Duarte, CA, (15)Hematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy, (16)Syndax Pharmaceuticals, Inc, Waltham, MA, (17)Incyte Corporation, Wilmington, DE, (18)Syndax Pharmaceuticals, Waltham, MA, (19)BMT & Cellular Therapy Program, Medical College of Wisconsin, Milwaukee, WI, (20)Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, (21)University Hospital of Regensburg, Regensburg, Germany, (22)Pediatric Stem Cell Transplant Program, Vanderbilt University Medical Center, Nashville, TN

https://tandem.confex.com/tandem/2024/meetingapp.cgi/Paper/23905

5 CAR19 Therapy Drives Expansion of Clonal Hematopoiesis and Associated Cytopenias

Friday, February 23, 2024

 9:30 AM - 9:45 AM CST

Stars at Night B2 & B3 (Ballroom Level, HBGCC)

Mark P. Hamilton, MD, PhD1, Brian Sworder, MD, PhD2, Stefan Alig, MD3, Zinaida Good, PhD1, Jan Boegeholz, PhD3, Joseph Schroers-Martin, MD4, John Tamaresis, Ph.D5, Mohammad Esfahani, PhD3, Ying Lu, PhD5, Mari Olsen6, Chih Long Liu, PhD7, Zachary Ehlinger, MS8, Moksha Desai9, Felicia Liu-Fei10, Lori S Muffly, MD, MS11, Robert S. Negrin, MD12, Sally Arai, MD13, Laura Johnston13, Robert Lowsky, MD13, Everett H. Meyer, MD, PhD14, Andrew R. Rezvani, MD13, Judith A. Shizuru, MD, PhD13, Wen-Kai Weng, MD, PhD13, Parveen Shiraz, MD15, Surbhi Sidana, MD13, Sushma Bharadwaj, MD16, Melody Smith, MD17, Saurabh Dahiya, MD18, Bita Sahaf, PhD19, Max Diehn, MD, PhD20, Matthew J. Frank, MD, PhD21, Crystal L. Mackall, M.D.22, David Kurtz, MD, PhD23, David B. Miklos, MD, PhD13 and Ash A. Alizadeh, MD, PhD23, (1)Center for Cancer Cell Therapy, Stanford University, Stanford, CA, (2)Department of Medicine, Division of Oncology, Stanford University, Stanford, CA, (3)Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, (4)Hematology and Oncology, Stanford, Stanford, CA, (5)Department of Biomedical Data Science, Stanford University School of Medicine, Stanford, CA, (6)Stanford University School of Medicine, Stanford, CA, (7)Medicine/Oncology, Stanford University School of Medicine, Stanford, CA, (8)Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford, CA, (9)Stanford Cancer Institute, Stanford, CA, (10)Stanford, Stanford, CA, (11)Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University, Stanford, CA, (12)Department of Medicine, Division of Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, CA, (13)Division of BMT and Cellular Therapy, Stanford University School of Medicine, Stanford, CA, (14)Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University School of Medicine, Stanford, CA, (15)Department of Medicine, Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA, (16)Blood and Marrow Transplantation & Cellular Therapy, Stanford University, Stanford, CA, (17)Medicine, Division of BMT-CT, Stanford, Stanford, CA, (18)BMT-CT, Stanford University, Stanford, CA, (19)Stanford University School of Medicine, Cancer Correlative Science Unit, Stanford Cancer Institute, Stanford, CA, (20)Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, (21)Division of BMT and Cellular Therapy, Stanford University, Stanford, CA, (22)Department of Pediatrics, Bass Center for Childhood Cancer and Blood Disorders, Stanford University School of Medicine, Stanfod, CA, (23)Hematology and Oncology, Stanford University, Stanford, CA

https://tandem.confex.com/tandem/2024/meetingapp.cgi/Paper/23576

56 Calcineurin Inhibitor-Free Graft-Versus-Host Disease (GVHD) Prophylaxis in Hematopoietic Cell Transplantation (HCT) with Myeloablative Conditioning Regimens (MAC) and HLA-Matched Donors: Long Term Follow up of BMT CTN 1301 Progress II Trial

Friday, February 23, 2024

 3:30 PM - 3:45 PM CST

Stars at Night B4 (Ballroom Level, HBGCC)

Marcelo C. Pasquini, MD, MS1, Robert Soiffer2, Brent Logan, PhD3, Manmeet Kaur, MS4, Steven M. Devine, MD5, Nancy Geller, PhD6, Sergio A. Giralt, MD7, Helen E. Heslop, MD8, Mary M. Horowitz, MD, MS9, Mark R. Litzow, MD10, Adam Mendizabal, PhD11, Lori S Muffly, MD, MS12, Eneida Nemecek, MD, MS, MBA13, Lynn C. O'Donnell, PhD14, Johannes Schetelig15, Leyla Shune16, Scott R. Solomon17, Sumithira Vasu, MBBS18, Dr. Vincent T. Ho, MD19, Miguel-Angel Perales, MD7 and Leo Luznik, MD20, (1)Department of Medicine, CIBMTR and Medical College of Wisconsin, Milwaukee, WI, (2)Dana-Farber Cancer Institute, Boston, MA, (3)CIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, (4)CIBMTR (Center for International Blood and Marrow Transplant Research), CIBMTR and the Medical College of Wisconsin, Milwaukee, WI, (5)CIBMTR® (Center for International Blood and Marrow Transplant Research), National Marrow Donor Program/Be The Match, Minneapolis, MN, (6)Office of Biostatistics Research, National Heart, Lung, and Blood Institute, Bethesda, MD, (7)Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY, (8)Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, (9)Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI, (10)Division of Hematology & Transplant Center, Mayo Clinic, Rochester, MN, (11)The EMMES Corporation, Rockville, MD, (12)Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University, Stanford, CA, (13)Center for Hematologic Malignancies - Knight Cancer Institute, Oregon Health & Science University, Portland, OR, (14)Division of Hematology, The Ohio State University, Columbus, OH, (15)CTU, DKMS, Dresden, Germany, (16)Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS, (17)Blood and Marrow Transplant Program, Northside Hospital Cancer Institute, Atlanta, GA, (18)Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, (19)Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, (20)Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD

https://tandem.confex.com/tandem/2024/meetingapp.cgi/Paper/23728

45 Real World Outcomes for AYA Patients with Relapsed/Refractory B-Cell ALL Receiving CD19-Directed CAR T-Cell Therapy

Friday, February 23, 2024

 3:45 PM - 4:00 PM CST

Stars at Night B2 & B3 (Ballroom Level, HBGCC)

Hannah Lust, MD1, Gregory Roloff, MD2, Liora Michal Schultz, MD3, Lori S Muffly, MD, MS4, Jessica Krugman, MD5, Ibrahim Aldoss, MD6, Soyang Kwon, PhD7, Michal Kubiak, MD8, Catherine J. Lee, MD, MS9, Ryan D. Cassaday, MD10, Bijal D. Shah, MD11, Christina Baggott, RN, PhD12, Noam E. Kopmar, MD13, Danielle Bradshaw, MD14, Marc Schwartz, MD15, Sean Tracy, MD, PhD16, Akash Mukherjee, MD17, Abdullah Ladha, MD18, George Yaghmour, MD18, Anjali S. Advani, MD19, Maryann Stefan20, Vamsi Kota, MD21, Muthu Veeraputhiran, MD, MPH22, Wendy Stock, MD23, Jenna Rossoff, MD24, Muna Qayed, MD, MSc25, Julie A Talano, MD26, Kevin J. Curran, MD27, Christine L Phillips, MD28, Nicole Karras, MD29, Vanessa A. Fabrizio, MD, MS30, Susanne H.C. Baumeister, MD31, Stacy Cooper, MD32, Michelle Hermiston, MD PhD33, Prakash Satwani, MD34, Margaret Macmillan, MD35, Samuel John, MD36 and Rawan G Faramand, MD37, (1)Pediatrics, Stem Cell Transplantation & Cellular Therapy, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, (2)Hematology/Oncology, University of Chicago, Chicago, IL, (3)Department of Pediatrics, Bass Center for Childhood Cancer and Blood Disorders, Stanford University School of Medicine, Stanford, CA, (4)Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University, Stanford, CA, (5)Pediatric Hematology/Oncology, NYU Grossman School of Medicine, New York, NY, (6)Hematology and HCT, City of Hope, Duarte, CA, (7)Stanley Manne Children's Research Institute, Northwestern University Feinberg School of Medicine, Chicago, IL, (8)Augusta University, Augusta, GA, (9)Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, (10)Fred Hutchinson Cancer Center, Seattle, WA, (11)H. Lee Moffitt Cancer Center, Tampa, FL, (12)Cancer Clinical Trials Office, Stanford University School of Medicine, Palo Alto, CA, (13)Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA, (14)BMT, Georgia Cancer Center at Augusta University, Augusta, GA, (15)University of Colorado, Aurora, CO, (16)University of Minnesota, Minneapolis, MN, (17)Hematology, Stem cell transplantation and Cellular therapy, University of Arkansas for Medical Sciences, Little Rock, AR, (18)University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, (19)Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, (20)Cleveland Clinic Foundation, Cleveland, OH, (21)Augusta University Medical Center, Augusta, GA, (22)Hematology Oncology, University of Arkansas for Medical Sciences, Little Rock, AR, (23)University of Chicago, Chicago, IL, (24)Pediatrics, Division of Hematology/Oncology/Stem Cell Transplant, Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, IL, (25)Emory University, Atlanta, GA, (26)Medical College of Wisconsin, Milwaukee, WI, (27)Memorial Sloan Kettering Cancer Center, New York, NY, (28)Cancer and Blood Diseases Institute, Cincinnati Children's Hospital, Cincinatti, OH, (29)Pediatrics, City of Hope, Duarte, CA, (30)Pediatric Bone Marrow Transplant/Cellular Therapies, University of Colorado, Anschutz Medical Campus, Colorado Children’s Hospital, Aurora, CO, (31)Harvard Medical School, Boston, MA, (32)Pediatric Oncology, Johns Hopkins, Baltimore, MD, (33)Division of Pediatric Allergy, Immunology, and Blood and Marrow Transplantation, UCSF Benioff Children's Hospital, San Francisco, CA, (34)Division of Pediatric Hematology, Oncology, and Stem Cell Transplantation, Department of Pediatrics, Columbia University Medical Center, New York, NY, (35)Pediatrics, Blood and Marrow Transplantation & Cellular Therapy Program, University of Minnesota, Minneapolis, MN, (36)Division of Pediatric Hematology/Oncology, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, (37)Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

https://tandem.confex.com/tandem/2024/meetingapp.cgi/Paper/22640

59 A Retrospective Analysis Comparing Orca-T to Post-Transplant Cyclophosphamide Based Allogeneic Hematopoietic Cell Transplant in Patients with Matched Unrelated Donors Receiving Myeloablative Conditioning

Friday, February 23, 2024

 4:15 PM - 4:30 PM CST

Stars at Night B4 (Ballroom Level, HBGCC)

Alexandra Gomez-Arteaga, M.D.1, Caspian Oliai, MD, MS2, Sagar S. Patel, MD3, Jeremy Pantin, MD4, Arpita P Gandhi, MD5, Amandeep Salhotra, MD6, Dr. Bhagirathbhai Dholaria, M.B.B.S.7, Edmund K. Waller, MD, PhD8, Samer A. Srour, MB ChB, MS9, Anna Pavlova, MD, PhD10, Irene Agodoa, MD10, James Scott McClellan, MD, PhD10, Nathaniel B. Fernhoff, PhD10, Mehrdad Abedi, MD11 and Everett H. Meyer, MD, PhD12, (1)Bone Marrow Transplant & Cell Therapy Program, Weill Cornell Medicine, Hematology and Medical Oncology, New York, NY, (2)UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA, (3)Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, (4)Sarah Cannon Transplant and Cellular Therapy Program at TriStar Centennial Medical Center, HCA Healthcare, Nashville, TN, (5)Center for Hematologic Malignancies - Knight Cancer Institute, Oregon Health & Science University, Portland, OR, (6)City of Hope, Duarte, CA, (7)Department of Medicine, Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, TN, (8)Bone Marrow and Stem Cell Transplant Center, Emory University Winship Cancer Institute, Atlanta, GA, (9)MD Anderson Cancer Center, Houston, TX, (10)Orca Bio, Menlo Park, CA, (11)Comprehensive Cancer Center, University of California, Davis, Sacramento, CA, (12)Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University School of Medicine, Stanford, CA

https://tandem.confex.com/tandem/2024/meetingapp.cgi/Paper/24051

64 Optimizing Outcomes with Myeloablative Conditioning in Older Patients: Efficacy and Safety of Precision Engineered Orca-T in Patients > 55 Years Old with Hematologic Malignancies

Saturday, February 24, 2024

11:15 AM - 11:30 AM CST

Stars at Night B2 & B3 (Ballroom Level, HBGCC)

Caspian Oliai, MD, MS1, Jeremy Pantin, MD2, Rasmus T Hoeg, MD3, Lori S Muffly, MD, MS4, Sagar S. Patel, MD5, Arpita Gandhi, MD6, Robert Lowsky, MD7, Amandeep Salhotra, MD8, Dr. Bhagirathbhai Dholaria, M.B.B.S.9, Edmund K. Waller, MD, PhD10, Samer A. Srour, MB ChB, MS11, Anna Pavlova, MD, PhD12, Nathaniel B. Fernhoff, PhD12, Irene Agodoa, MD12, James Scott McClellan, MD, PhD12, Mehrdad Abedi, MD3, Robert S. Negrin, MD13 and Everett H. Meyer, MD, PhD13, (1)UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA, (2)Sarah Cannon Transplant and Cellular Therapy Program at TriStar Centennial Medical Center, HCA Healthcare, Nashville, TN, (3)Comprehensive Cancer Center, University of California, Davis, Sacramento, CA, (4)Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University, Stanford, CA, (5)Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, (6)Oregon Health Sciences University, Portland, OR, (7)Division of BMT and Cellular Therapy, Stanford University School of Medicine, Stanford, CA, (8)City of Hope, Duarte, CA, (9)Department of Medicine, Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, TN, (10)Bone Marrow and Stem Cell Transplant Center, Emory University Winship Cancer Institute, Atlanta, GA, (11)MD Anderson Cancer Center, Houston, TX, (12)Orca Bio, Menlo Park, CA, (13)Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University School of Medicine, Stanford, CA

https://tandem.confex.com/tandem/2024/meetingapp.cgi/Paper/24121

 

ASTCT SCIENTIFIC WORKSHOPS

Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-like Syndrome

Wednesday, February 21, 2024

10:53 AM - 11:11 AM CST

225CD (Meeting Level, HBGCC)

Matthew J. Frank, MD, PhD, Division of BMT and Cellular Therapy, Stanford University, Stanford, CA

https://tandem.confex.com/tandem/2024/meetingapp.cgi/Paper/24351

 

Biology of Relapse after Transplant and Cellular Therapy

Wednesday, February 21, 2024

6:00 PM - 6:30 PM CST

Stars at Night B2 & B3 (Ballroom Level, HBGCC)

Melody Smith, MD, Medicine, Division of BMT-CT, Stanford, Stanford, CA

https://tandem.confex.com/tandem/2024/meetingapp.cgi/Paper/24371

 

GvHD Prevention with Novel Agents and Graft Manipulation

Friday, February 23, 2024

11:25 AM – 11:50 AM CST

Stars at Night B1 (Ballroom Level, HBGCC)

Everett H. Meyer, MD, PhD, Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University School of Medicine, Stanford, CA

https://tandem.confex.com/tandem/2024/meetingapp.cgi/Paper/23190

 

Getting to Yes: Provider and Payer Perspectives on Navigating the Prior Authorization

Saturday, February 24, 2024

10:42 AM – 11:04 AM CST

217 (Meeting Level, HBGCC)

Gary Goldstein, Blood and Marrow Transplantation and Cellular Therapy Program, Stanford Health Care, Palo Alto, CA

https://tandem.confex.com/tandem/2024/meetingapp.cgi/Paper/23137

 

Getting Your Money: Presentation and Panel Discussion on What It Takes to Implement Medicare’s Cost-Based Reimbursement for Allogeneic SCT

Saturday, February 24, 2024

2:45 AM – 3:00 PM CST

217 (Meeting Level, HBGCC)

Gary Goldstein, Blood and Marrow Transplantation and Cellular Therapy Program, Stanford Health Care, Palo Alto, CA

https://tandem.confex.com/tandem/2024/meetingapp.cgi/Paper/24203

 

LBA-2 Absence of Evidence for Pervasive CAR19 Driven T-Cell Lymphomagenesis Revealed By Comprehensive Genomic Profiling of an Index Tumor.

Saturday, February 24, 2024

 3:35 PM - 3:55 PM CST

Stars at Night B4 (Ballroom Level, HBGCC)

Mark P. Hamilton, MD, PhD1, Takeshi Sugio, MD, PhD2, Troy Noordenbos, MD, PhD2, Shuyu Shi2, Max Diehn, MD, PhD3, Dita Gratzinger, MD, PhD4, David B. Miklos, MD, PhD5, Ash A. Alizadeh, MD, PhD6 and Zinaida Good, PhD1, (1)Center for Cancer Cell Therapy, Stanford University, Stanford, CA, (2)Divisions of Hematology and Oncology, Stanford University, Palo Alto, CA, (3)Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, (4)Department of Pathology, Stanford University, Palo Alto, CA, (5)Division of BMT and Cellular Therapy, Stanford University School of Medicine, Stanford, CA, (6)Hematology and Oncology, Stanford University, Stanford, CA

https://tandem.confex.com/tandem/2024/meetingapp.cgi/Paper/24327

 

Stanford BMT-CT ASTCT Abstracts 2024:

210 Clofarabine and High-Dose Melphalan Reduced Intensity Conditioning Regimen for Allogeneic Stem Cell Transplantation

Sandy On1, Walter Domingo1, Edna Cheung1 and Laura Johnston2, (1)Stanford Health Care, Stanford, CA, (2)Division of BMT and Cellular Therapy, Stanford University School of Medicine, Stanford, CA

https://tandem.confex.com/tandem/2024/meetingapp.cgi/Paper/23356

237 - CD22 CAR T-Cells Manufactured in Prodigy System and in Bag Culture Yield Equivalent Responses for B-ALL

Alexandra Dreyzin, MD MS1, Anne Marijn Kramer, MD, PhD2, Bonnie Yates, MSN, CNP3, Hao-Wei Wang, MD, PhD4, Bita Sahaf, PhD5, Constance Yuan, MD, PhD6, Zachary Ehlinger, MS7, Sunita Patil, MS8, Kathryn Martin9, Lori S Muffly, MD, MS10, Haneen Shalabi, DO3, Kara L Davis, D.O.7, Matthew J. Frank, MD, PhD11, Liora Michal Schultz, MD12, Gregoire Altan-Bonnet, PhD13, Crystal L. Mackall, M.D.14, Naomi Taylor, MD, PhD3, Steven Highfill, Ph.D.15, Steven Feldman, PhD7, David F. Stroncek, MD16, Sneha Ramakrishna, MD7 and Nirali N. Shah, MD, MHSc3, (1)Center for Cancer and Blood Disorders, Children's National Hospital, Washington, DC, (2)Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA, (3)Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, (4)Laboratory of Pathology, NCI, NIH, Bethesda, MD, (5)Stanford University School of Medicine, Cancer Correlative Science Unit, Stanford Cancer Institute, Stanford, CA, (6)Laboratory of Pathology, National Institutes of Health/ National Cancer Institute, Bethesda, MD, (7)Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford, CA, (8)Cancer Correlative Science Unit, Stanford University, Stanford, CA, (9)Center for Cell Engineering, National Institute of Health, Bethesda, MD, (10)Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University, Stanford, CA, (11)Division of BMT and Cellular Therapy, Stanford University, Stanford, CA, (12)Department of Pediatrics, Bass Center for Childhood Cancer and Blood Disorders, Stanford University School of Medicine, Stanford, CA, (13)Laboratory of Integrative Cancer Immunology, National Cancer Institute, Bethesda, MD, (14)Department of Pediatrics, Bass Center for Childhood Cancer and Blood Disorders, Stanford University School of Medicine, Stanford, CA, (15)Department of Transfusion Medicine, NIH/Clinical Center, Bethesda, MD, (16)Department of Transfusion Medicine, National Institutes of Health, Bethesda, MD

https://tandem.confex.com/tandem/2024/meetingapp.cgi/Paper/22952

239 Real World Outcomes of Older Adults and Frail Patients with Relapse/Refractory Multiple Myeloma Receiving Idecabtagene Vicleucel

Othman Salim Akhtar, MD, MBBS1, Hamza Hashmi, M.D.2, Temitope Oloyede, MD, MPH, CPH1, Ruta Brazauskas, PhD1,3, Matthew Bye, MPH1, Surbhi Sidana, MD4, Doris K Hansen, MD5, Nausheen Ahmed6, Christopher Ferreri7, Aimaz Afrough, MD8, Larry D. Anderson Jr., MD, PhD8, Binod Dhakal, MD9, Devender Dhanda10, Lohith Gowda, MD, MRCP (UK)11, Melanie Harrison12, Amani Kitali10, Heather J Landau, MD13, Abu-Sayeef Mirza, MD, MPH14, Dr. Jinalben Patel, MPH1, Pallavi Patwardhan12, Muzaffar H. Qazilbash, MD15, Krina K. Patel, MD, MSc16, Taiga Nishihori, MD5,17, Siddhartha MD Ganguly, MD, FACP18, Marcelo C. Pasquini, MD, MS1, Saad Z. Usmani, MD MBA FACP19 and Ciara Louise Freeman, MD, PhD20, (1)CIBMTR® (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, (2)Memorial Sloan Kettering Cancer Center, Charleston, SC, (3)Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, WI, (4)Division of BMT and Cellular Therapy, Stanford University School of Medicine, Stanford, CA, (5)Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, (6)Division of Hematological Malignancy and Cellular Therapeutics, University of Kansas Health System, Kansas City, KS, (7)Hematologic Oncology and Blood Disorders, Levine Cancer Institute Atrium Health, Charlotte, NC, (8)Myeloma, Waldenstrom's and Amyloidosis Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, (9)BMT and Cellular Therapy, Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, (10)Bristol Myers Squibb, Princeton, NJ, (11)Yale Cancer Center and Yale School of Medicine, New Haven, CT, (12)Bristol Meyers Squibb, Princeton, NJ, (13)Bone Marrow Transplant Service, Division of Hematology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, (14)Hematology, Yale University School of Medicine, New Haven, CT, (15)Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, (16)The University of Texas MD Anderson Cancer Center, Houston, TX, (17)Department of Oncologic Sciences, Morsani College of Medicine, University South of Florida, Tampa, FL, (18)Houston Methodist Hospital and Neal Cancer Center, Houston, TX, (19)Memorial Sloan Kettering Cancer Center, New York, NY, (20)Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

https://tandem.confex.com/tandem/2024/meetingapp.cgi/Paper/22998

248 Impact of Complete Response (CR) on Long-Term Survival Among Patients Receiving Axicabtagene Ciloleucel (axi-cel) for Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL)

Armin Ghobadi, MD1, Theodora Anagnostou, MD2, Jacques Azzi, MD2, Mehdi Hamadani, MD3, Brent Logan, PhD3, Michael T Hemmer, MS4, Sairah Ahmed, MD5, Sushma Bharadwaj, MD6, Alex F. Herrera, MD7, Caron A. Jacobson, MD, MMSc8, Frederick L. Locke, MD9, Hai-Lin Wang, MPH4, Myrna Nahas, MD4, Timothy Best, PhD4, Sachin Vadgama, MParm, MSc4, Zhen-Huan Hu, MPH4 and Marcelo C. Pasquini, MD, MS3, (1)Washington University, St. Louis, MO, (2)Mount Sinai Hospital System, New York, NY, (3)Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI, (4)Kite, a Gilead Company, Santa Monica, CA, (5)Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, (6)Blood and Marrow Transplantation & Cellular Therapy, Stanford University, Stanford, CA, (7)City of Hope National Medical Center, Duarte, CA, (8)Dana-Farber Cancer Institute, Boston, MA, (9)Moffitt Cancer Center, Tampa, FL

https://tandem.confex.com/tandem/2024/meetingapp.cgi/Paper/23341

256 Bridging Therapy in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Receiving Standard of Care Brexucabtagene Autoleucel: Results from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA)

Chenyu Lin, MD1, Dr. Stephanie B. Tsai, MD2, Gregory Roloff, MD3, Amy Zhang, MPH4, Ibrahim Aldoss, MD5, Noam E. Kopmar, MD6, Simone E. Dekker, MD, PhD7, Nikeshan Jeyakumar, MD8, Vishal Gupta, MD9, Timothy E O'Connor, MD10, Kaitlyn C Dykes, MD11, Mohamed Ahmed, MD12, Dr. Bhagirathbhai Dholaria, M.B.B.S.13, Hector Zambrano14, Danielle Bradshaw, MD15, Aaron C. Logan, MD PhD16, Sean Tracy, MD, PhD17, Michal Kubiak, MD18, Melhem M Solh, MD19, Santiago Mercadal, MD20, Marc Schwartz, MD21, Akash Mukherjee, MD22, Minoo Battiwalla, MD, MS23, Paul J. Shaughnessy24, Navneet S. Majhail, MD, MS23, Luke Mountjoy, MD25, Shahbaz Malik, MD26, John Mathews, MD27, Dr. Abdullah Ladha, MD MPH28, Anjali S. Advani, MD29, Maryann Stefan30, Caitlin Guzowski31, Rasmus T Hoeg, MD32, Talal Hilal, MD33, Jozal W. Moore, MD34, Kristen M O'Dwyer, MD35, Joshua P Sasine, MD36, Catherine J Lee, MD20, Vamsi Kota, MD37, Divya Koura, MD18, Muthu Veeraputhiran, MD, MPH38, Betsy Blunk, BSN, RN, BMTCN14, Jessica T. Leonard, MD39, Caspian Oliai, MD40, Veronika Bachanova, MD, PhD41, Wendy Stock, MD42, Vinod Pullarkat, MD5, Ryan D. Cassaday, MD43, Katharine Miller, PhD4, Lori S Muffly, MD, MS44, Ahmed Galal, MD45, Bijal D. Shah, MD46 and Rawan G Faramand, MD47, (1)Division of Hematologic Malignancies and Cellular Therapy, Duke University School of Medicine, Durham, NC, (2)Hematology/Oncology, Loyola University Medical Center, Maywood, IL, (3)Hematology/Oncology, University of Chicago, Chicago, IL, (4)Department of Medicine, Quantitative Sciences Unit, Stanford University School of Medicine, Stanford, CA, (5)Hematology and HCT, City of Hope, Duarte, CA, (6)Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA, (7)Department of Medicine, Oregon Health & Science University, Portland, OR, (8)Stanford University School of Medicine, Stanford, CA, (9)University of California Los Angeles, Los Angeles, CA, (10)Loyola University Medical Center, Maywood, IL, (11)University of California San Diego, La Jolla, CA, (12)Cedars-Sinai Medical Center, Los Angeles, CA, (13)Medicine, Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, TN, (14)Sarah Cannon Transplant and Cellular Therapy Network, HCA Healthcare, Nashville, TN, (15)BMT, Georgia Cancer Center at Augusta University, Augusta, GA, (16)Div. Hematology, BMT, & Cellular Therapy, University of California, San Francisco, San Francisco, CA, (17)University of Minnesota, Minneapolis, MN, (18)Augusta University, Augusta, GA, (19)Blood and Marrow Transplant Program, Northside Hospital Cancer Institute, Atlanta, GA, (20)University of Utah, Salt Lake City, UT, (21)University of Colorado, Aurora, CO, (22)Hematology, Stem cell transplantation and Cellular therapy, University of Arkansas for Medical Sciences, Little Rock, AR, (23)Sarah Cannon Transplant and Cellular Therapy Program at TriStar Centennial Medical Center, HCA Healthcare, Nashville, TN, (24)Sarah Cannon Transplant and Cellular Therapy Program at Methodist Hospital, HCA Healthcare, San Antonio, TX, (25)Colorado Blood Cancer Institute at HealthONEs Sarah Cannon Cancer Institute at Presbyterian/St. Luke's Medical Center, HCA Healthcare, Denver, CO, (26)Sarah Cannon Transplant and Cellular Therapy Program at St. David's South Austin Medical Center, HCA Healthcare, Austin, TX, (27)Texas Oncology, PA, HCA Healthcare, Dallas, TX, (28)Dept. of Hematology, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, (29)Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, (30)Cleveland Clinic Foundation, Cleveland, OH, (31)Northside Hospital,, Atlanta, GA, (32)Comprehensive Cancer Center, University of California, Davis, Sacramento, CA, (33)Mayo Clinic, Phoenix, AZ, (34)Department of Medicine, Division of Hematology and Oncology, University of Rochester Medical Center, Wilmot Cancer Institute, Rochester, NY, (35)University of Rochester,, Rochester, NY, (36)Medicine, Division of Hematology and Oncology, University of California, Los Angeles, Los Angeles, CA, (37)Augusta University Medical Center, Augusta, GA, (38)Hematology Oncology, University of Arkansas for Medical Sciences, Little Rock, AR, (39)Center for Hematologic Malignancies - Knight Cancer Institute, Oregon Health & Science University, Portland, OR, (40)University of California, Los Angeles, Los Angeles, CA, (41)Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN, (42)University of Chicago, Chicago, IL, (43)Fred Hutchinson Cancer Center, Seattle, WA, (44)Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University, Stanford, CA, (45)Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, NC, (46)H. Lee Moffitt Cancer Center, Tampa, FL, (47)Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

https://tandem.confex.com/tandem/2024/meetingapp.cgi/Paper/23436

263 Analysis of PET-CT Derived Radiomic Biomarkers with Efficacy, Safety, and Expansion of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL)

Sushma Bharadwaj, MD1, Eric Lau, DO2,3, Ayesha Hashmi4, Mark P. Hamilton, MD, PhD5, Alexandria Jensen, PhD6, Anmol Goyal, MD1, Mallika Marar, MD, MBA7, Caroline Lee, MD8, Snegha Ananth, MD9, Bita Sahaf, PhD10, Jayasindhu Mallampet11, Zachary Ehlinger, MS12, Shriya Syal, MS13, Sunita Patil, MS13, Henry Guo, MD, PhD14, Melody Smith, MD15, Wen-Kai Weng, MD, PhD16, Matthew J. Frank, MD, PhD17, Michael S Binkley, MD, MS18, David B. Miklos, MD, PhD16 and Saurabh Dahiya, MD19, (1)Blood and Marrow Transplantation & Cellular Therapy, Stanford University, Stanford, CA, (2)Blood and Marrow Transplantation & Cellular Therapy, Stanford University, Palo Alto, CA, (3)Hematology and Oncology, Palo Alto Medical Foundation, Palo Alto, CA, (4)Department of Radiation Oncology, Stanford University, Palo Alto, CA, (5)Center for Cancer Cell Therapy, Stanford University, Stanford, CA, (6)Quantitative Sciences Unit, Stanford University, Stanford, CA, (7)Department of Radiation Oncology, Stanford University, Stanford, CA, (8)Division of Hematology and Oncology, Stanford University, Palo Alto, CA, (9)Hematology/Oncology, University of Texas Health Science Center at San Antonio, San Antonio, TX, (10)Stanford University School of Medicine, Cancer Correlative Science Unit, Stanford Cancer Institute, Stanford, CA, (11)Stanford university school of medicine, Stanford, CA, (12)Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford, CA, (13)Cancer Correlative Science Unit, Stanford University, Stanford, CA, (14)Department of Radiology, Stanford University, Palo Alto, CA, (15)Medicine, Division of BMT-CT, Stanford, Stanford, CA, (16)Division of BMT and Cellular Therapy, Stanford University School of Medicine, Stanford, CA, (17)Division of BMT and Cellular Therapy, Stanford University, Stanford, CA, (18)Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, (19)BMT-CT, Stanford University, Stanford, CA

https://tandem.confex.com/tandem/2024/meetingapp.cgi/Paper/23556

265 CD19 Antigen Density Down-Regulation at Time of Progression in Large B-Cell Lymphoma Patients Treated with Axicabtagene Ciloleucel

Jay Spiegel, MD1, Jean S. Oak, MD, PhD2, Anmol Goyal, MD3, Scott Bornheimer, PhD4, Allison Irvine, PhD4, Rhine R. Shen, PhD5, Katherine A. Kong6, Sushma Bharadwaj, MD3, Wen-Kai Weng, MD, PhD7, Melody Smith, MD8, Matthew J. Frank, MD, PhD9, Saurabh Dahiya, MD10 and David B. Miklos, MD, PhD7, (1)Department of Medicine, Division of Transplant and Cellular Therapy, University of Miami Health System, Miami, FL, (2)Department of Pathology, Stanford University, Stanford, CA, (3)Blood and Marrow Transplantation & Cellular Therapy, Stanford University, Stanford, CA, (4)BD Biosciences, San Jose, CA, (5)Kite, a Gilead Company, Santa Monica, CA, (6)Stanford University, Stanford, CA, (7)Division of BMT and Cellular Therapy, Stanford University School of Medicine, Stanford, CA, (8)Medicine, Division of BMT-CT, Stanford, Stanford, CA, (9)Division of BMT and Cellular Therapy, Stanford University, Stanford, CA, (10)BMT-CT, Stanford University, Stanford, CA

https://tandem.confex.com/tandem/2024/meetingapp.cgi/Paper/23596

271 Real Time, Point-of-Need Measurement of Blood CD19 CAR-T Vector Load Is Concordant with Standard Ddpcr Method

Jay Spiegel, MD1, Jean S. Oak, MD, PhD2, Anmol Goyal, MD3, Scott Bornheimer, PhD4, Allison Irvine, PhD4, Rhine R. Shen, PhD5, Katherine A. Kong6, Sushma Bharadwaj, MD3, Wen-Kai Weng, MD, PhD7, Melody Smith, MD8, Matthew J. Frank, MD, PhD9, Saurabh Dahiya, MD10 and David B. Miklos, MD, PhD7, (1)Department of Medicine, Division of Transplant and Cellular Therapy, University of Miami Health System, Miami, FL, (2)Department of Pathology, Stanford University, Stanford, CA, (3)Blood and Marrow Transplantation & Cellular Therapy, Stanford University, Stanford, CA, (4)BD Biosciences, San Jose, CA, (5)Kite, a Gilead Company, Santa Monica, CA, (6)Stanford University, Stanford, CA, (7)Division of BMT and Cellular Therapy, Stanford University School of Medicine, Stanford, CA, (8)Medicine, Division of BMT-CT, Stanford, Stanford, CA, (9)Division of BMT and Cellular Therapy, Stanford University, Stanford, CA, (10)BMT-CT, Stanford University, Stanford, CA

https://tandem.confex.com/tandem/2024/meetingapp.cgi/Paper/23664

279 Neuroaxonal Injury, but Not Astrocyte Injury, Is Associated with CAR T Cell Related Icans

Omar Hameed Butt, MD, PhD1, Alice Y Zhou, MD PhD1, John F. DiPersio, MD, PhD2, David B. Miklos, MD, PhD3, Matthew J. Frank, MD, PhD4, Beau M Ances, MD, PhD5 and Armin Ghobadi, MD6, (1)Medicine, Washington University in Saint Louis, Saint Louis, MO, (2)Bone Marrow Transplantation & Leukemia Section, Division of Oncology, Washington University School of Medicine, St. Louis, MO, (3)Division of BMT and Cellular Therapy, Stanford University School of Medicine, Stanford, CA, (4)Division of BMT and Cellular Therapy, Stanford University, Stanford, CA, (5)Washington University in Saint Louis, Saint Louis, MO, (6)Division of Oncology, Washington University School of Medicine, St. Louis, MO

https://tandem.confex.com/tandem/2024/meetingapp.cgi/Paper/23797

293 Trial in Progress: Phase 1/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells (VCAR33) in Patients with Relapsed or Refractory Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation

Nirali N. Shah, MD, MHSc1, Jacques Azzi, MD2, Brenda Cooper, MD3, Abhinav Deol, MD4, John F. DiPersio, MD, PhD5, Divya Koura, MD6, John Magenau, MD7, Brian McClune, DO8, Lori S Muffly, MD, MS9, Muhammad Umair Mushtaq, MD10, Rupa Narayan, MD11, Hyung C. Suh12, Sritama Nath, PhD13, Jennifer Whangbo, MD, PhD13 and Guenther Koehne, M.D., PhD14, (1)Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, (2)Division of Hematology & Medical Oncology, Cellular Therapy and Bone Marrow Transplant, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, (3)Adult Hematologic Malignancies & Stem Cell Transplant Section, Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH, (4)Karmanos Cancer Institute, Wayne State University, Detroit, MI, (5)Washington University School of Medicine in St. Louis, St. Louis, MO, (6)University of San Diego, San Diego, CA, (7)Rogel Cancer Center, University of Michigan, Ann Arbor, MI, (8)Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, (9)Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University, Stanford, CA, (10)Division of Hematologic Malignancies and Cellular Therapeutics, Kansas University Medical Center, Kansas City, KS, (11)Massachusetts General Hospital, Boston, MA, (12)John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, (13)Vor Biopharma, Cambridge, MA, (14)Miami Cancer Institute | Baptist Health South Florida, Miami, FL

https://tandem.confex.com/tandem/2024/meetingapp.cgi/Paper/23938

313 Omidubicel-Onlv for Allogeneic Transplantation (allo-HCT) in Patients with Hematologic Malignancies: Results of a Multicenter Open-Label Expanded Access Program (EAP)

Mitchell Horwitz, MD1, Gary J. Schiller, MD2, Dr. Stephanie B. Tsai, MD3, Andrew R. Rezvani, MD4, Richard T. Maziarz, MD5, Uri Goshen, M.Med.Sc.6, Stuart Levy, MPA7, Aurelie Schwarzbach, MSc6, Dr. Roei Mazor, MD, PhD7 and Patrick J. Stiff, MD3, (1)Adult Stem Cell Transplant Program, Division of Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC, (2)Division of Hematology-Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, (3)Hematology/Oncology, Loyola University Medical Center, Maywood, IL, (4)Division of BMT and Cellular Therapy, Stanford University School of Medicine, Stanford, CA, (5)Center for Hematologic Malignancies - Knight Cancer Institute, Oregon Health & Science University, Portland, OR, (6)Gamida Cell Ltd., Jerusalem, Israel, (7)Gamida Cell, Ltd., Jerusalem, Israel

https://tandem.confex.com/tandem/2024/meetingapp.cgi/Paper/22951

368 Assessing Treatment Response in Cutaneous Sclerosis after Allogeneic Hematopoietic Cell Transplantation: A Chronic Gvhd Consortium Study

Joseph A. Pidala, MD, PhD1, Lynn Onstad, MSc2, Emily Baumrin, MD MSCE3, Dr. Paul A. Carpenter, MBBS2, Dr. Corey Cutler, MD, MPH, FRCPC4, Sally Arai, MD5, Carrie L. Kitko, MD6, George L Chen, MD7 and Stephanie J Lee, MD, MPH8, (1)Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, (2)Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, (3)Penn Medicine, Philadelphia, PA, (4)Division of Transplantation and Cellular Therapy, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, (5)Division of BMT and Cellular Therapy, Stanford University School of Medicine, Stanford, CA, (6)Pediatric Stem Cell Transplant Program, Vanderbilt University Medical Center, Nashville, TN, (7)Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, (8)Fred Hutchinson Cancer Center, Seattle, WA

https://tandem.confex.com/tandem/2024/meetingapp.cgi/Paper/23710

417 Novel Subsets of Human Invariant Natural Killer T Cells, Including a Temra-like CD4-CD8- Population, Revealed through Single Cell RNA-Sequencing

Dr. Melissa Mavers, MD, PhD1, Derek Hollingsworth, MS2, Reyka Jayasinghe, PhD3, Chaiyaporn Boonchalermvichian, MD, PhD4, Biki Gupta, PhD4, Hao Yan, PhD4, Jeanette Baker4, Beruh Dejene2, Kenneth I Weinberg, MD5 and Robert S. Negrin, MD4, (1)Department of Pediatrics, Division of Hematology and Oncology, Washington University School of Medicine in St. Louis, St. Louis, MO, (2)Department of Pediatrics, Division of Hematology, Oncology, Stem Cell Transplantation and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, (3)Department of Medicine, Washington University School of Medicine, Saint Louis, MO, (4)Department of Medicine, Division of Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, CA, (5)Department of Pediatrics/ Division of Hematology, Oncology, Stem Cell Transplantation, and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA

https://tandem.confex.com/tandem/2024/meetingapp.cgi/Paper/23214

428 Immune Reconstitution and Infectious Complications Following BCMA-Targeted CAR-T Therapy in Relapsed/Refractory Multiple Myeloma (RRMM)

Maria Moscvin, MD1, Anmol Goyal, MD2, Alexandria Jensen, PhD3, Dr. David J Epstein, MD4, Vanna Hovanky5, Lekha Mikkilineni, MD5, Leslie Bennett, MSN, RN, ACM6, Theresa M. Latchford, RN, MS, CNS, BMTCN, AOCNS7, Sally Arai, MD5, Sushma Bharadwaj, MD2, Matthew J. Frank, MD, PhD8, Saurabh Dahiya, MD9, Lori S Muffly, MD, MS10, David B. Miklos, MD, PhD5, Hitomi Hosoya, MD PhD5 and Surbhi Sidana, MD5, (1)Medicine, Stanford University School of Medicine, Palo Alto, CA, (2)Blood and Marrow Transplantation & Cellular Therapy, Stanford University, Stanford, CA, (3)Quantitative Sciences Unit, Stanford University, Stanford, CA, (4)Department of Medicine, Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, CA, (5)Division of BMT and Cellular Therapy, Stanford University School of Medicine, Stanford, CA, (6)Division of BMT and Cellular Therapy, Stanford Department of Medicine, Stanford, CA, (7)Department of Medicine, Division of Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, CA, (8)Division of BMT and Cellular Therapy, Stanford University, Stanford, CA, (9)BMT-CT, Stanford University, Stanford, CA, (10)Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University, Stanford, CA

https://tandem.confex.com/tandem/2024/meetingapp.cgi/Paper/24036

440 Age-Related Differences in Utilization of Allogeneic HCT for Acute Myeloid Leukemia in California: Results of a Population-Based, Novel Linked Dataset

Christa L. Meyer, MS1, Theresa H.M. Keegan, PhD2, Ann Brunson, MS2, Jeffery J. Auletta, MD3,4, Lindsay M. Morton, PhD5, Ted Wun, MD2, Sara J Schonfeld, PhD5, Bryan Valcarcel, MD, MPH5, Renata Abrahao, MD, MSc, PhD2, Rafeek A. Yusuf, MD, PhD3 and Lori S Muffly, MD, MS6, (1)Center for International Blood and Marrow Transplant Research, NMDP, Minneapolis, MN, (2)Center for Oncology Hematology Outcomes Research and Training (COHORT), Division of Hematology and Oncology, University of California Davis Comprehensive Cancer Center, Sacramento, CA, (3)CIBMTR® (Center for International Blood and Marrow Transplant Research), National Marrow Donor Program/Be The Match, Minneapolis, MN, (4)Divisions of Hematology/Oncology/BMT and Infectious Diseases, Nationwide Children’s Hospital, Columbus, OH, (5)Radiation Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, (6)Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University, Stanford, CA

https://tandem.confex.com/tandem/2024/meetingapp.cgi/Paper/23467

442 The Impact of Social Determinants of Health on Brexucabtagene Autoleucel Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Timothy E O'Connor, MD1, Chenyu Lin, MD2, Gregory Roloff, MD3, Amy Zhang, MPH4, Ibrahim Aldoss, MD5, Rawan G Faramand, MD6, Noam E. Kopmar, MD7, Kaitlyn C Dykes, MD8, Nikeshan Jeyakumar, MD9, Simone E. Dekker, MD, PhD10, Vishal Gupta, MD11, Mohamed Ahmed, MD12, Aaron C. Logan, MD PhD13, Hector Zambrano14, Danielle Bradshaw, MD15, Santiago Mercadal, MD16, Marc Schwartz, MD17, Sean Tracy, MD, PhD18, Michal Kubiak, MD19, Akash Mukherjee, MD20, Navneet S. Majhail, MD, MS21, Minoo Battiwalla, MD, MS21, Luke Mountjoy, MD22, Shahbaz Malik, MD23, John Mathews, MD24, Paul J. Shaughnessy25, Abdullah Ladha, MD26, Anjali S. Advani, MD27, Maryann Stefan28, Caitlin Guzowski29, Rasmus T Hoeg, MD30, Talal Hilal, MD31, Jozal W. Moore, MD32, Kristen M O'Dwyer, MD33, Joshua P Sasine, MD34, Melhem M Solh, MD35, Catherine J. Lee, MD, MS36, Vamsi Kota, MD37, Divya Koura, MD19, Muthu Veeraputhiran, MD, MPH38, Betsy Blunk, BSN, RN, BMTCN14, Jessica T. Leonard, MD39, Caspian Oliai, MD, MS40, Veronika Bachanova, MD, PhD41, Wendy Stock, MD42, Vinod Pullarkat, MD5, Ryan D. Cassaday, MD43, Bijal D. Shah, MD44, Katharine Miller, PhD4, Lori S Muffly, MD, MS45, Ahmed Galal, MD46, Dr. Stephanie B. Tsai, MD47 and Dr. Bhagirathbhai Dholaria, M.B.B.S.48, (1)Loyola University Medical Center, Maywood, IL, (2)Division of Hematologic Malignancies and Cellular Therapy, Duke University School of Medicine, Durham, NC, (3)Hematology/Oncology, University of Chicago, Chicago, IL, (4)Department of Medicine, Quantitative Sciences Unit, Stanford University School of Medicine, Stanford, CA, (5)Hematology and HCT, City of Hope, Duarte, CA, (6)Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, (7)Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA, (8)University of California San Diego, La Jolla, CA, (9)Stanford University School of Medicine, Stanford, CA, (10)Department of Medicine, Oregon Health & Science University, Portland, OR, (11)University of California Los Angeles, Los Angeles, CA, (12)Cedars-Sinai Medical Center, Los Angeles, CA, (13)Div. Hematology, BMT, & Cellular Therapy, University of California, San Francisco, San Francisco, CA, (14)Sarah Cannon Transplant and Cellular Therapy Network, HCA Healthcare, Nashville, TN, (15)BMT, Georgia Cancer Center at Augusta University, Augusta, GA, (16)University of Utah, Salt Lake City, UT, (17)University of Colorado, Aurora, CO, (18)University of Minnesota, Minneapolis, MN, (19)Augusta University, Augusta, GA, (20)Hematology, Stem cell transplantation and Cellular therapy, University of Arkansas for Medical Sciences, Little Rock, AR, (21)Sarah Cannon Transplant and Cellular Therapy Program at TriStar Centennial Medical Center, HCA Healthcare, Nashville, TN, (22)Colorado Blood Cancer Institute at HealthONEs Sarah Cannon Cancer Institute at Presbyterian/St. Luke's Medical Center, HCA Healthcare, Denver, CO, (23)Sarah Cannon Transplant and Cellular Therapy Program at St. David's South Austin Medical Center, HCA Healthcare, Austin, TX, (24)Texas Oncology, PA, HCA Healthcare, Dallas, TX, (25)Sarah Cannon Transplant and Cellular Therapy Program at Methodist Hospital, HCA Healthcare, San Antonio, TX, (26)University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, (27)Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, (28)Cleveland Clinic Foundation, Cleveland, OH, (29)Northside Hospital,, Atlanta, GA, (30)Comprehensive Cancer Center, University of California, Davis, Sacramento, CA, (31)Mayo Clinic, Phoenix, AZ, (32)Department of Medicine, Division of Hematology and Oncology, University of Rochester Medical Center, Wilmot Cancer Institute, Rochester, NY, (33)University of Rochester,, Rochester, NY, (34)Medicine, Division of Hematology and Oncology, University of California, Los Angeles, Los Angeles, CA, (35)Blood and Marrow Transplant Program, Northside Hospital Cancer Institute, Atlanta, GA, (36)Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, (37)Augusta University Medical Center, Augusta, GA, (38)Hematology Oncology, University of Arkansas for Medical Sciences, Little Rock, AR, (39)Center for Hematologic Malignancies - Knight Cancer Institute, Oregon Health & Science University, Portland, OR, (40)UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA, (41)Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN, (42)University of Chicago, Chicago, IL, (43)Fred Hutchinson Cancer Center, Seattle, WA, (44)H. Lee Moffitt Cancer Center, Tampa, FL, (45)Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University, Stanford, CA, (46)Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, NC, (47)Hematology/Oncology, Loyola University Medical Center, Maywood, IL, (48)Medicine, Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, TN

https://tandem.confex.com/tandem/2024/meetingapp.cgi/Paper/23510

505 Implementing Preferred Language Nutrition Education Classes Virtually for the Outpatient Myeloma Patient Population Pre-Transplant

Tara Coghlin Dickson, MS, RD, CSSD, FAND and Kylie Chen, MS, RD, Clinical Nutrition, Stanford Health Care, Stanford, CA

https://tandem.confex.com/tandem/2024/meetingapp.cgi/Paper/22650

521 Clinical Experience with Cranial Nerve Impairment in the Cartitude-1, Cartitude-2 Cohorts a, B and C, and Cartitude-4 Studies of Ciltacabtagene Autoleucel (Cilta-cel)

Niels W.C.J. van de Donk1, Surbhi Sidana, MD2, Jordan M Schecter3, Carolyn C Jackson3, Nikoletta Lendvai, MD PhD4, Kevin C. De Braganca, MD5, Ana Slaughter6, Carolina Lonardi7, Philip Vlummens8, Helen Varsos, MS, RPh3, Christina Corsale3, Deepu Madduri3, Shirin Jadidi3, Junchen Gu9, Hao Zhao9, Katherine Li10, Erin Lee11, Loreta Marquez3, Man Zhao12, Tzu-min Yeh3, Diana Chen13, Erika Florendo14, Nitin Patel15, Muhammad Akram14, Jaime Gallego Perez-Larraya16 and Paula Rodriquez-Otero17, (1)Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, Netherlands, (2)Division of BMT and Cellular Therapy, Stanford University School of Medicine, Stanford, CA, (3)Janssen Research & Development, Raritan, NJ, (4)Weill Cornell Medical College, New York, NY, (5)Janssen R&D, Raritan, NJ, (6)Cilag GmbH International, Zug, Switzerland, (7)Janssen, Buenos Aires, Argentina, (8)Janssen Research & Development, Beerse, Belgium, (9)Janssen Research & Development, Spring House, PA, (10)Janssen Research & Development, Springhouse, PA, (11)Janssen Research & Development, Titusville, NJ, (12)IQVIA, Shanghai, China, (13)Janssen Research & Development, Shanghai, China, (14)Legend Biotech USA, Piscataway, NJ, (15)Legend Biotech USA Inc., Somerset, NJ, (16)Clínica Universidad de Navarra, IDISNA, Pamplona, Spain, (17)Clínica Universidad de Navarra, CIMA, CIBERONC, IDISNA, Pamplona, Spain

https://tandem.confex.com/tandem/2024/meetingapp.cgi/Paper/23492

523 Idecabtagene Vicleucel (ide-cel) Chimeric Antigen Receptor T-Cell for Plasma Cell Leukemia (PCL): A Multicenter Experience

Gliceida Maria Galarza Fortuna, MD1, Surbhi Sidana, MD2, Vanna Hovanky2, Jack Khouri3, Danai Dima4, Mehmet H. Kocoglu, MD5, Peter Forsberg6, Christopher Ferreri7, Shebli Atrash8, Peter M. Voorhees, MD9, Hamza Hashmi, M.D.10, James Davis, PharmD, BCOP11, Mahmoud Gaballa12, Eric Anto13, Gabe De Avila14, Lauren Peres, MPH, PhD15, Krina K. Patel, MD, MSc16, Doris K Hansen, MD17 and Douglas Sborov, MD18, (1)Hematology and Oncology, University of Utah/Huntsman Cancer Institute, Salt Lake City, UT, (2)Division of BMT and Cellular Therapy, Stanford University School of Medicine, Stanford, CA, (3)Blood and Marrow Transplant Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, (4)Cleveland Clinic Foundation, Cleveland, OH, (5)Transplantation & Cellular Therapy Program, Division of Hematology/Oncology, Department of Internal Medicine, Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, (6)UCHealth Blood Disorders and Cell Therapies Center - Anschutz Medical Campus, Aurora, CO, (7)Hematologic Oncology and Blood Disorders, Levine Cancer Institute Atrium Health, Charlotte, NC, (8)US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, KS, (9)Department of Hematologic Oncology and Blood Disorders, Atrium Health, Levine Cancer Institute, Charlotte, NC, (10)Department of Hematology-Oncology, Medical University of South Carolina, Charleston, NY, (11)The Medical University of South Carolina (MUSC), Charleston, SC, (12)MD Anderson Cancer Center, Houston, TX, (13)Department of population health sciences, University of Utah, Salt Lake City, UT, (14)H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, (15)Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, (16)MD Anderson Cancer Center, University of Texas, Houston, TX, (17)Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, (18)University of Utah/Huntsman Cancer Institute, Salt Lake CIty, UT

https://tandem.confex.com/tandem/2024/meetingapp.cgi/Paper/23554

572 Catching Community Onset C.Diff in BMT/CT Units

Diana Mazur, RN, MSN, CNS, BMTCN, Blood and Marrow Transplant, Stanford Health Care, Palo Alto, CA and Diana Mazur, BSN, RN, BMTCN, Stanford Healthcare, Palo Alto, CA

https://tandem.confex.com/tandem/2024/meetingapp.cgi/Paper/23210

581 Development of a Patient Itinerary for Chimeric Antigen Receptor T Cell (CAR-T) Therapy and Blood and Marrow Transplant (BMT) Recipients and Donors

Leslie Bennett, MSN, RN, ACM1, Erin Eidam, RN, BSN, BMTCN2, Zoe Rabine, RN, BSN, BMTCN3, Theresa M. Latchford, RN, MS, CNS, BMTCN, AOCNS4, Ann General, BSN, RN, PCCN5, Felipe Araya Ventura, BSN, RN, BMTCN6, Cynthia Morowitz, RN, BSN, CNRN5 and Margarita Perez-Machovec, RN, BSN5, (1)Division of BMT and Cellular Therapy, Stanford Department of Medicine, Stanford, CA, (2)Division of BMT and Cellular Therapy, Stanford Health Care, Stanford, CA, (3)Blood and Marrow Transplantation and Cellular Therapy, Stanford Health Care, Stanford, CA, (4)Department of Medicine, Division of Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, CA, (5)Division of BMT and Cellular Therapy, Stanford Health Care, Stanford, CA, (6)Stanford Health Care, Stanford, CA

https://tandem.confex.com/tandem/2024/meetingapp.cgi/Paper/23907